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1. Introduction 
Free tissue transfer is a safe and reliable mode of tissue reconstruction. Though it is the 
highest rung on the reconstructive ladder, this method of reconstruction is utilized by a 
multitude of surgical specialties including: plastic and reconstructive, orthopaedic, 
otolaryngology, and oral maxillofacial. There are multiple indications for free tissue transfer. 
A few examples are: skeletal defects after debridement for osteomyelitis, breast 
reconstruction, various trunk and extremity defects, and most recently composite tissue 
allotransplantation – primarily face and hand transplantion. Despite employing perfect 
microsurgical technique, flap failure caused by anastomotic thrombosis continues to occurs 
in complicated and uncomplicated microvascular anastomosis. Many pharmacologic agents 
have been studied experimentally and clinically both in the treatment and prophylaxis of 
microvascular thrombosis; however, there still remains no consensus as to what the optimal 
pharmacologic regimen should be. In this chapter, we discuss the reported incidence of flap 
failure caused by microvascular thrombosis, review the pathophysiology of thrombus 
formation, review the anti-thrombotic pharmacologic agents commonly used for 
prophylaxis, and overview the current methods of flap monitoring. 
2. Complications of free tissue transfer 
The most common and feared complication of microvascular anastomosis is graft failure 
secondary to arterial or venous thrombosis. It is reported that this occurs in five to ten 
percent of cases1. Thrombosis is the body’s natural defense mechanism to prevent blood 
loss. When a vascular insult occurs, the body employs platelets and fibrin to seal the defect. 
The physiologic process is initiated by the presence of tissue factor when injury to the 
vascular intima occurs. This results in the extrinsic pathway of the coagulation cascade to 
begin. Tissue factor activates factor X, which in turn activates thrombin, eventually leading 
to the activation of fibrinogen. When discussing free tissue transfer, the vascular intima has 
been injured as a result of the microsurgical anastomosis. It is imperative that the inherent 
process of coagulation be prevented. The use of pharmacologic anticoagulation has been a 
point of contention in free tissue transfer with no clinical study yielding conclusive evidence 
that it is the most effective means to prevent thrombosis. 
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In the vascular surgery literature, the use of pharmacologic anticoagulation has been shown 
to improve outcomes and patency rates. It has been described in the microvascular literature 
that three main pharmacologic agents exist and are used as an adjunct to preventing 
thrombosis. They are heparin, aspirin, and dextran. A multitude of pharmacologic protocols 
exist. Nearly all are based on anecdotal data Various doses of aspirin, heparin at 
subtherapeutic levels without titration to partial thromboplastin time, and intraluminal 
irrigation prior to completion of the anastomosis are a few examples. The authors explore 
the various pharmacologic agents and the evidence that exists in the literature. In addition, 
we review the methods for monitoring and protecting the fragile initial uncomplicated 
microsurgical anastomosis in order to prevent complication and reoperation. 
3. Pharmacologic agents 
ASPIRIN 
Aspirin (acetylsalicylic acid) is part of the non-steroidal anti-inflammatory drug group 
(NSAIDs) and a well known medication for analgesia, antipyretic, and anti-inflammatory 
purposes. Its mechanism of action was described in 1971 by the British pharmacologist John 
Robert Vane2 from the Royal College of Surgeons in London, and noted to prevent the 
production of thromboxanes and prostaglandins. It was shown that aspirin irreversibly 
inactivates the cyclooxygenase (COX) enzyme which is required for the synthesis of both 
thromboxane and prostaglandin. Aspirin functions differently when compared to other 
NSAIDs in that it acetylates the serine residue in the active site of the COX enzyme, whereas 
other NSAIDs bind reversibly. This property affords aspirin the ability to inhibit platelet 
aggregation, the primary role of thromboxane A2, for the life of the platelet. Furthermore, 
aspirin decreases endothelial production of prostacyclin which acts as a vasodilator and 
inhibitor of platelet aggregation. It has been shown that low doses (40-80mg) selectively 
inhibit platelet-derived thromboxane by 95% while only slightly decreasing endothelial 
derived prostacyclin (35%). However, the aspirin dose of 325mg decreases prostacyclin 
production by 75%. The side effect profile for aspirin includes bronchospasm, peptic ulcers, 
gastritis, risk of gastric hemorrhage with concurrent use of alcohol of warfarin, hemolytic 
anemia in glucose-6-phosphate dehydrogenase deficiency3, gout exacerbation, and Reye’s 
syndrome4(potentially fatal disease affecting the brain, liver, and other organs in children 
with concurrent viral illness). Despite the side effect profile, surgeons performing vascular 
anastomosis and free tissue transfer take advantage of the platelet aggregation inhibition 
properties of aspirin. 
HEPARIN 
Heparin was discovered in 1916 and noted to be a highly sulfated glycosaminoglycan with 
the highest negative charge density of any known biological molecule5. Heparin as well as 
enoxaparin (a low molecular weight derivative) has been shown to be effective in 
preventing deep venous thrombosis (DVT) and pulmonary embolism (PE) in at risk 
patients6. The primary function of heparin is the binding of antithrombin III (ATIII) which 
renders it active due to increased flexibility of the reactive site loop of the enzyme as a result 
of a conformational change7. Due to this, ATIII inactivates thrombin induced activation  
of factors V and VIII as well as factor Xa, which are all important factors in the  
coagulation cascade. Heparin can be administered as a once or multi daily dose for 
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prevention/prophylaxis of DVT and/or PE in at risk hospitalized patients. The dose 
depends on the formulation/preparation of heparin, patient renal function, and patient 
weight. The side effect profile of heparin most notably includes heparin-induced 
thrombocytopenia (HIT) with or without thrombosis (HITT). In this phenomenon, 
antibodies are produced against heparin when it is bound to a protein (platelet factor 4) 
which forms a complex that attaches to a receptor on the surface of a platelet resulting in 
activation of platelet microparticles leading to the formation of a thrombis8. As a result, 
thrombocytopenia ensues and the patient is also at risk of hemorrhage. Additionally, other 
side effects include elevation of serum aminotransferases which is not a result of liver 
dysfunction, but rather a drug effect, and hyperkalemia as a result of heparin-induced 
aldosterone suppression. As a result of heparin’s mechanism and proven effects, systemic 
therapy has been employed by cardiothoracic and vascular surgeons to maintain patency of 
vascular anastomosis. 
DEXTRAN 
Dextran is a complex branched glucan with weights ranging from 3 to 2000 kilodaltons 
made from the polysaccharide fermentation of sucrose. The use of dextran in microsurgery 
revolves around its ability to decrease vascular thrombosis by reducing blood viscosity. This 
effect is hinged on dextran’s binding of platelets, vascular endothelium, and erythrocytes 
which increases the overall negative charge thereby reducing aggregating properties. As a 
result, low molecular weight dextrans impair platelet function, prolong bleeding time, 
destabilize fibrin polymerization, act to expand blood volume by acting as potent osmotic 
agents, and decreased stability of platelet thrombus. The side effect profile of dextran is 
relatively small yet severe. The list includes anaphylaxis, pulmonary edema, cerebral 
edema, platelet dysfunction, and volume overload. Occasionally, acute renal failure has 
been described as a result of dextran 
4. Anticoagulation use in free tissue transfer 
In a study by Davies9 in 1982, a questionnaire was dispersed to 73 microsurgery centers 
worldwide. In the responses, 825 free flaps were evaluated which showed that 691 surgeons 
used varying methods of anticoagulation, and 161 surgeons used no form of anticoagulation 
including no intraluminal heparin irrigation. In the anticoagulation group, it was found that 
there was an 89% success rate of free flap survival versus an 88% success rate in the non-
anticoagulation group. This study was flawed by a lack of control for anticoagulation 
protocol which made inferences difficult to determine from the results. 
In 1997, a study by Glicksman10 surveyed microsurgeons’ practices over a four year 
period and administered a retrospective questionnaire to investigate anticoagulation 
regimens. From these findings, 96% of respondents used some form of antithrombotic 
treatment. The various regimens employed by surgeons included: dextran, heparin, and 
aspirin. Of these surgeons who used dextran, 75% gave dextran intraoperatively and 
continued treatment for three to seven days. Other surgeons used heparin as an 
intraoperative bolus of 3000U to 5000U. Additionally, aspirin at a dose of 325mg once a 
day for up to fourteen days postoperatively was also documented. It is notable that this 
type of variety exists in that there is no empirical evidence in the literature to support 
these various protocols. 
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5. Evidence for aspirin 
In 2005, a study by Chien11 showed that in 216 head and neck reconstruction cases a post 
operative anticoagulation regimen of aspirin 325mg daily and administering heparin at 
5000U subcutaneous twice a day showed similar flap survival and hematoma rates versus 
other anticoagulation protocols. This study however was limited by a lack of an internal 
control. 
6. Evidence for heparin 
A prospective multi-institutional study by Khouri12 in 1998, which included 23 centers over 
a six month period, yielded 493 free tissue transfers to be evaluated. The results of the study 
showed a 4.1% flap failure rate, 8.3% intraoperative thrombosis, and 9.9% postoperative 
thrombosis requiring reexploration. It was found that administering only postoperative 
subcutaneous heparin therapy was responsible for a statistically significant decrease in the 
incidence of thrombosis. Further, it was concluded that intraluminal heparin, intraoperative 
systemic heparin, aspirin, and dextran had no impact on thrombosis rates and overall 
outcome. Unfortunately, this study was limited by the diversity of anticoagulation protocols 
used by each participating center. 
In an animal model conducted by Ritter13 in 1998, these authors investigated whether 
unfractionated heparin, low molecular weight heparin, could improve the patency of 
microvascular anastomoses. They concluded that due to the hematoma rate being present only in 
the unfractionated heparin group, that low molecular weight heparin is the anticoagulant of 
choice to both maintain vascular anastomotic patency and minimize hemorrhage. 
7. Evidence against heparin 
Pugh14 in 1996 conducted a retrospective study evaluating the use of anticoagulants during 
surgery. It was determined that of the 15 patients who underwent microvascular free flap 
reconstruction for wound coverage, the use of heparin in addition to other anticoagulants 
had a higher associated hematoma rate versus the use of dextran and aspirin, both 
separately and together. This finding confirms the current regimen employed by most 
surgeons that the use of a single anticoagulant is necessary. 
8. Evidence against dextran 
While heparin, aspirin, and dextran all have pharmacologic properties making them 
wonderful agents to prevent anastomotic thrombosis and flap failure, they each have a side 
effect profile that is not benign. Many of the side effects are quite rare, and they each have 
the ability to cause bleeding and possibly overwhelming hemorrhage. Further, dextran has 
the ability to cause devastating systemic complications including anaphylaxis and volume 
overload leading to cerebral and/or pulmonary edema.  
Disa15 in 2003 found that patients receiving dextran had up to a 7.2 times increased rate of 
developing a systemic complication versus patients receiving aspirin. As a result, low 
molecular weight dextran was removed from use at that institution as an option for 
anticoagulation after head and neck reconstruction.  
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Further, in a study from 2003 by Sun16, it was concluded that dextran was not necessary for 
microvascular anastomosis thrombosis prevention as the dextran free arm of their review 
had a 100% patency rate versus 96% in the dextran use group. Additionally, they mention 
the serious side effects of dextran and note that they can be prevented by not using this 
pharmacologic agent.  
9. No evidence of efficacy 
In a study from 1994, Kroll evaluated 517 free tissue transfers17. It was shown that the 
relationship between the use of anticoagulants and prevention of flap loss or prevention 
of thrombosis could not be established. Further, it was also concluded that low-dose 
(bolus heparin) in the perioperative period did not significantly increase the risk of 
hematoma. 
Deutinger18 in 1998 conducted a study evaluating the influence of dextran versus heparin as 
well as the technique of the anastomosis in free tissue transfer. In the study, 81 patients 
received dextran and heparin postoperatively, and 123 patients received heparin alone. It 
was found that there was no statistically significant difference in the rate of thrombosis in 
these two groups. However, an 8.9% (p < 0.02) higher rate of thrombosis was found with 
end-to-end anastomosis as compared with end-to-side. 
In 2004, Veravuthipakorn19 conducted a study to determine whether a pharmacologic agent 
is necessary to prevent anastomotic thrombosis and flap failure. They discussed 40 cases of 
free tissue transfer and replantation in which no antithrombotic agent was instituted 
intraoperatively or postoperatively. Their results showed one partial flap loss and two 
replantantion losses due to severe crush injuries. They state that technique is paramount in 
microvascular anastomosis. It was concluded that antithrombotic agents alone do not play a 
significant role in anastomotic patency. 
Ashjian20 in 2007 looked at 505 microvascular free tissue transfers to reconstruct oncologic 
defects, in which they allocated 260 patients to receive postoperative aspirin for five days 
whereas 245 patients received low molecular weight heparin. It was concluded that 
postoperative anticoagulation choice has no statistically significant effect on the incidence of 
free flap complications in terms of the following outcome variables: microvascular 
thrombosis, partial or total flap loss, hematoma, bleeding, deep venous thrombosis, 
pulmonary embolism, and death. They stated that aspirin and low molecular weight 
heparin therapy demonstrate equivalent outcomes when used as a single-agent in the 
posoperative period. The authors also concluded that intraoperative systemic heparin had 
no statistically significant effect on prevention of microvascular thrombosis, and a single 
dose of intraoperative heparin does not prevent thrombosis. They believe that intraoperative 
anticoagulation does not affect flap survival. 
In 2010, Brands21 conducted a review of the literature which showed that there is currently 
no consensus in the literature to prevent thrombosis after microvascular free flap 
reconstruction. Conclusions were drawn that non-pharmacologic means such as smoking 
cessation and meticulous microvascular surgery plays a crucial role in the outcome. The 
authors stated that it has not been determined as to which preoperative, intraoperative, or 
postoperative protocol for pharmacologic anticoagulation regimen is most effective to 
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prevent thrombosis, and that the decision should be made based on the individual patient 
and the risk profile for the development of thrombosis. 
10. Conclusions 
From these powerful studies in the current literature, it is evident that surgeons utilize 
preoperative, intraoperative, and postoperative anticoagulation to prevent the catastrophic 
negative outcome of vascular thrombosis leading to flap failure and necrosis. The specific 
method used by surgeons thus far is based upon operator preference. These highlighted 
studies provide evidence that there is no definitive protocol in microsurgery to prevent 
thrombosis; although there are some important insights that can be agreed upon after a 
careful review of the literature. 
First and foremost, the rate of flap failure in microvascular surgery is very low, with success 
rates generally >95%. When flaps fail, it is not always a result of vascular thrombosis, but 
rather can be for a variety of other reasons as well, including improper flap inset, systemic 
hypotension, or perhaps even as a result of certain medications that causes severe 
vasoconstriction (which is certainly occasionally necessary as a life saving measure). When 
rates of flap failure are so low, and when they have multiple causes, it requires an extremely 
large study in order to show a statistically significant difference in any type of intervention. 
Thus far, such a study does not exist in regards to anticoagulation. 
It is fair to say, based on one of the largest prospective studies (REF 12), that at the very 
least, subcutaneous heparin injections should be considered, if no other anticoagulant is to 
be used. Although this was certainly a flawed study, it was one of the largest studies, 
drawing upon the experiences of many of the most reputable microsurgery centers at that 
time. Because of the well established benefit of subcutaneous heparin in DVT prophylaxis, 
along with the long period of immobilization that these patients invariably experience at 
least during surgery, subcutaneous heparin does appear to be a prudent option. Currently, 
in our own institution, low molecular weight heparin injections has generally replaced 
regular heparin for DVT prophylaxis. It is also the opinion of the authors, that the risk of 
Dextran prophylaxis, as pointed out by the Disa study (REF 15), is enough evidence to 
preclude its use in our practice, particularly considering the lack of any other clinical data to 
support its use in preventing thrombosis in microvascular surgery. In summary, although 
anticoagulation may have a limited benefit in preventing thrombosis in microvascular 
surgery, it is far more important to perform a technically perfect operation, with painstaking 
attention to detail along every step of the procedure, including patient selection, pre-
operative behavior modification (such as smoking cessation), flap selection and design, flap 
inset, and post-operative flap monitoring and care. The use of the venous coupling systems, 
as well as the recently available intra-operative fluoresence imaging system using 
indocyanine green dye are two technological advances that may prove to be quite beneficial 
in improving outcomes in microvascular surgery. 
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